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Abstract
Background: G-protein inwardly rectifying potassium channel 1 (GIRK1) is thought to play a role
in cell proliferation in cancer, and GIRK1 gene expression level may define a more aggressive
phenotype. We detected GIRK1 expression in tissue specimens from patients with non-small cell
lung cancers (NSCLCs) and assessed their clinical characteristics.
Methods:  Using reverse transcription-polymerase chain reaction (RT-PCR) analyses, we
quantified the expression of GIRK1 in 72 patients with NSCLCs to investigate the relationship
between GIRK1 expression and clinicopathologic factors and prognosis.
Results: In 72 NSCLC patients, 50 (69%) samples were evaluated as having high GIRK1 gene
expression, and 22 (31%) were evaluated as having low GIRK1 gene expression. GIRK1 gene
expression was significantly associated with lymph node metastasis, stage (p = 0.0194 for lymph
node metastasis; p = 0.0207 for stage). The overall and stage I survival rates for patients with high
GIRK1 gene expressed tumors was significantly worse than for those individuals whose tumors had
low GIRK1 expression (p = 0.0004 for the overall group; p = 0.0376 for stage I).
Conclusions: These data indicate that GIRK1 may contribute to tumor progression and GIRK1
gene expression can serve as a useful prognostic marker in the overall and stage I NSCLCs.
Background
Lung cancer is one of the leading causes of cancer death in
North America [1]. Lung cancer is divided into two mor-
phological types: small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). The results of surgery still
remain unsatisfactory; even in stage I NSCLC (no lymph
node metastasis and no distant metastasis) about 30% of
patients die due to disease recurrence within 5 years after
curative resection [2]. Despite major advances in cancer
treatment in the past decades, the prognosis of patients
with NSCLC has improved only minimally [1]. A new
knowledge of the molecular pathogenesis of cancer has
emerged from investigative advances in the field of molec-
ular biology [3]. Increased knowledge of the biologic role
of genetic changes has provoked an intriguing search for
clinical applications of these alterations [4], and has ena-
bled the more aggressive tumors from the less aggressive
ones to be distinguished [5].
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G-protein inwardly rectifying potassium channels (GIRK)
are found in both the heart and the brain, where they are
associated with a slowing of the heart rate and suppres-
sion of neuronal response [6]. The channel found in the
sinoatrial node and on atrial myocytes is formed from the
homologous channel subunits GIRK1 and GIRK4 [7].
Although the function of GIRK1 still remains unclear
except in cell proliferation in cancer, GIRK1 gene expres-
sion has been found to correlate with lymph node metas-
tasis in breast carcinomas [8], but the correlation with
GIRK1 gene expression and prognosis has never been ana-
lyzed in NSCLC. To our knowledge, this is the first report
to analyze the prognostic influence of GIRK1 gene expres-
sion in NSCLC and the possible associations between this
parameter and other clinical factors. In this study, we used
RT-PCR for detecting GIRK1 in tumor tissues. We com-
pared with GIRK1 gene expression with autocrine motility
factor-receptor (AMF-R) gene expression, known as a
marker of lymph node metastasis and tumor progression,
and we investigated how GIRK1 gene expression is related
to tumor progression and prognosis in a series of 72 cases
of curatively resected NSCLC.
Methods
Tissue specimens
Tumor tissue was collected from 72 patients with NSCLC
who underwent curative surgery between 1993 and 1995
at Department of Surgery, Teikyo University School of
Medicine. Patients who died within one month after sur-
gery and patients with a past history of another cancer
were excluded from the study. Of the 72 patients
included, 52 were men and 20 were women and their ages
ranged from 34 to 80 years (mean of 66 years). With
regard to histological type, 41 were adenocarcinomas, 28
were squamous cell carcinomas and 3 were large cell lung
carcinomas. The lesions of these 72 patients were staged
on both operative and pathologic findings according to
the UICC TNM classification (1997) [9]. There were 24
patients with stage IA, 11 patients with stage IB, 1 patients
with stage IIA, 13 patients with stage IIB, and 23 patients
with stage IIIA. These patients were performed curative
operation with lymph node dissection. The mean follow-
up time was 52.0 months (range, 2.7–120.0 months).
Freshly removed pulmonary cancer tissues for RNA extrac-
tion were immediately frozen in liquid nitrogen and
stored at -80°C until further use. And in five of the cases,
adjacent normal pulmonary material from the same
patient was also used in this study. Tissue samples to be
used for hematoxylin-and-eiosin were fixed in formalin
and paraffin embedded.
Reverse transcription-polymerase chain reaction (RT-
PCR) analysis
Total RNA was purified from fresh soft tissues by the acid
guanidinium-thiocyanate procedure [10]. The human
pulmonary adenocarcinoma cell line PC-14 (Riken Gene
Bank Co., Ltd. Tokyo, Japan) was used as a positive con-
trol. All the RNA (5 µg) was used for cDNA synthesis, and
the first-standard cDNA solution was then used for the
PCR, with primers designed to amplify a 230 bp sequence
(sense primer sequence: 5'-GGGATTTGGACAT-
GGCTAAGTC-3' ; antisense primer sequence: 5'-GGCCT-
GTTTTCATTCTCTTAACTGATAC-3'). The reaction
mixture was overlaid with 20 µl of mineral oil. PCR was
performed for forty cycles (10 s at 95°C; 60 s at 60°C, and
120 s at 72°C) as previously described [8]. S14 cDNA
amplification using the same temperature profile for 30
cycles served as the internal control [11]: the sense and
antisense primers for S14 cDNA amplification were 5'-
GGCAGACCGAGATGAATCCTC-3' and 5'-CAGGTCCAG-
GGGTCTTGGTCC-3'. The amplified DNA samples were
electrophoresed on 1% agarose gels, and photographed
with a Polaroid camera. Densitometric analysis of the
photographic negatives was used for band quantification.
Specimen classification based on RT-PCR results
The densitometric value obtained for the GIRK1 band of a
given tumor tissue sample was divided by the correspond-
Agarose gel electrophoresis of RT-PCR amplified 230 bp  GIRK1 cDNA, and 143 bp S14 DNA as internal PCR control Figure 1
Agarose gel electrophoresis of RT-PCR amplified 230 bp 
GIRK1 cDNA, and 143 bp S14 DNA as internal PCR control. 
Lane 1, size marker; Lane 2, human pulmonary adenocarci-
noma cell line PC-14 (positive control); Lane 3, pulmonary 
adenocarcinoma with high GIRK1 expression. Lane 4, pulmo-
nary adenocarcinoma with low GIRK1 expression. Lane 5, 
squamous cell carcinoma with high GIRK1 expression. Lane 
6, squamous carcinoma with low GIRK1 expression. Lane 7, 
large cell carcinoma with high GIRK1 expression. Lane 8, 
large cell carcinoma with low GIRK1 expression. Lane 9, and 
Lane 10, normal pulmonary tissue with low GIRK1 
expression.BMC Cancer 2004, 4:79 http://www.biomedcentral.com/1471-2407/4/79
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ing S14 value, and was referred to as the GIRK1 gene
expression rate. The level of the GIRK1 mRNA expression
in PC-14 cell line is elevated. The expression ratio of the
tumor was then divided by that of the human pulmonary
adenocarcinoma cell line PC-14 to obtain the GIRK1 con-
servation rate. When the conservation rate of a given spec-
imen was  0.8, it was considered to indicate high
expression of the GIRK1 gene, and if the rate was < 0.8, it
was defined as low expression.
Comparison with GIRK1 gene expression and AMF-R gene 
expression
To ascertain whether links between GIRK1 gene expres-
sion and another gene expression, known as a marker of
lymph node metastasis and tumor progression in NSCLC,
we examined the relationships between GIRKI gene
expression and AMF-R gene expression in 46 cases [12].
The studies of AMF-R gene expression were performed as
described previously [12]. The expression ratio of the
tumor was divided by that of the cell line PC-14, and the
conservation rate of a given specimen was larger than the
mean ratio, it was considered to indicate high expression
of the AMF-R gene, and if the rate was lower than the
mean ratio, it was defined as low expression of the AMF-R
gene.
Statistical analysis
All data regarding the clinical and histopathological vari-
ables were stored in a Macintosh computer. The Stat View
program (Aracus Concepts, Berkeley, Ca, USA) was used
for all statistical analyses. The relationship between the
incidence of GIRK1 expression and clinico-pathologic
factors, and AMF-R gene expression was examined by the
chi-squared test with Fisher correlation. Survival curves
were calculated using the Kaplan-Meier method and ana-
lyzed by the log-rank test. Statistical significance was iden-
tified as p < 0.05.
Results
Detection of GIRK1 using RT-PCR in NSCLC tissues
To determine the number of PCR cycles appropriate for
quantification, from 20 and 50 cycles of PCR were per-
formed, in 5-cycle increments. The expression ratios of
GIRK1 to S14 were reasonably constant 35 to 45 cycles
(data not shown). Therefore, in the subsequent experi-
ments the values obtained at 40 cycles were defined as the
expression of the target genes. Using forty RT-PCR cycles,
we found that the ratio of GIRK1/cell line PC-14 expres-
sion ranged from 0 to 2.2 (means, 0.8) in tumor speci-
mens (Fig. 1). Of 72 NSCLCs studied, 50 (69%) were
classified as GIRK1 high gene expression, and 22(31%)
were classified as having GIRK1 low gene expression. Five
adjacent normal pulmonary materials ranged from 0 to
0.1 (means = 0.1), and all of them were classified as
GIRK1 low gene expression.
Relationship between GIRK1 gene expression and 
clinicopathological factors
The relationships between GIRK1 gene expression and
various clinicopathological factors are shown in Table 1.
There were no statistically significant relationships
between gene expression and age, gender, T factor and his-
tology. In contrast, GIRK1 gene expression was associated
with N factor and stage (p = 0.0194 for lymph node
metastasis, p = 0.0207 for stage).
Table 1: Correlation between GIRK1 gene expression and 
various clinicopathologic factors in patients with lung cancer
Variable GIRK1 p value
Low expression 
(n = 22) (31%)
High expression 
(n = 50) (69%)
Age at surgery (yrs)
≤60 8 (11 %) 19 (26 %)
>60 14 (20 %) 31 (43 %) 0.90
Sex
Male 17 (24 %) 35 (48 %)
Female 5 (7 %) 15 (21 %) 0.53
Tumor status
T1 10 (14 %) 11 (15 %)
T2 10 (14 %) 25 (35 %) 0.07
T3 2 (3 %) 14 (19 %)
Nodal status
N0 17 (24 %) 26 (36 %)
N1 3 (4 %) 3 (4 %) 0.02
N2 2 (3 %) 21 (29 %)
Stage
IA/IB 16 (22 %) 19 (26 %)
IIA/IIB 4 (6 %) 10 (14 %) 0.02
III A 2 (3 %) 21 (29 %)
Histology
Adenocarcinoma 15 (21 %) 26 (36 %)
Squamous cell 
carcinoma
6 (8 %) 22 (30 %) 0.40
Large cell 
carcinoma
1 (2 %) 2 (3 %)
Table 2: Relationship between GIRK1 gene expression results 
and autocrine motility factor receptor (AMF-R) gene expression 
results
GIRK1 low 
expression
GIRK1 high 
expression
Total
AMFR low expression 7 (15 %) 6 (13 %) 13 (28 %)
AMFR high expression 7 (15 %) 26 (57 %) 33 (72 %)
P = 0.03BMC Cancer 2004, 4:79 http://www.biomedcentral.com/1471-2407/4/79
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The relationships between GIRK1 gene expression and 
AMF-R gene expression
Of 46 NSCLCs studied, 33 (72%) were classified as AMF-
R high gene expression, and 13(28%) were classified as
having AMF-R low gene expression. In most GIRK1 high
gene expression cases, AMF-R gene was also expressed. As
shown Table 2, the results of GIRK1 gene expression
agreed significantly with AMF-R gene and 72% of cases had no dis-
crepancy (p = 0.0303).
Association of tumor GIRK1 gene expression and survival
The survival was compared between the high GIRK1 gene
expression group and the low GIRK1 gene expression
group in overall, stage I and stage II/III. Figures 2 and 3
show the significance in survival between the high GIRK1
gene expression group and the low GIRK1 gene expression
group in overall and stage I groups (P = 0.0004 for the
overall group; P = 0.0376 for the stage I group). Although
the 5-year survival in low GIRK1 gene expression group is
better than that in the high GIRK1 gene expression group
in the stage II/III, there is not a difference in survival
between the 2 groups (Figure 4).
Discussion
In spite of significant advances in surgery and the use of
new, more effective chemotherapeutic regimens, the over-
all 5-year survival of patients with NSCLC is 17% [13].
Identification of new prognostic factors might be of value
in directing therapy and intensifying follow-up for a select
group of patients. Lymph node metastasis and stage are
the most powerful prognostic markers for NSCLC. Identi-
fying new genes that are associated with tumor growth,
metastasis, and prognosis is very important in advancing
the understanding of cancer biology.
Human carcinomas exhibit hyperpolarized membrane
potential as compared with surrounding normal tissue
[14,15]. GIRK1 acts to conduct potassium ions into the
cell rather than out of the cell, and play a role in maintain-
ing membrane potential. Though GIRK1 act to hyperpo-
Overall survival of 72 lung cancer patients according to  GIRK1 amplification Figure 2
Overall survival of 72 lung cancer patients according to 
GIRK1 amplification. Survival curves were calculated by the 
Kaplan-Meier method, and statistical evaluation was deter-
mined by the log-rank test (p = 0.0004).
Survival curves of the patients with stage I NSCLC on the  basis of GIRK1 amplification Figure 3
Survival curves of the patients with stage I NSCLC on the 
basis of GIRK1 amplification. A significant difference was seen 
between the 2 groups (p = 0.0376).
Survival curves of the patients with stage II / III NSCLC on  the basis of GIRK1 amplification Figure 4
Survival curves of the patients with stage II / III NSCLC on 
the basis of GIRK1 amplification. A significant difference was 
not seen between the 2 groups.BMC Cancer 2004, 4:79 http://www.biomedcentral.com/1471-2407/4/79
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larizing the cell membrane, the function of GIRK1 still
remains completely unclear in cancer. Cell proliferation
and the density of intracellular potassium are controlled
at specific stages of the cell cycle [16], and cell membrane
potential indeed changes during the cell cycle [14]. And
GIRK1 is reported to play a role in cell proliferation [3].
Receptors known to activate GIRK1 belong to the family
of G-protein coupled receptors, and the G-protein-cou-
pled receptors are reported to be able to induce cell prolif-
eration and activate a pathway leading to angiogenesis in
tumor [17]. GIRK1 gene overexpression is reported to fol-
low a general trend of increasing expression if lymph node
metastasis is involved in breast carcinomas [8]. Though
the mechanical role of GIRK1 in lymph node metastasis in
cancer is not clear, angiogenesis is reported to be corre-
lated with lymph node metastasis, tumor progression and
poor prognosis in most of solid tumors [18,19]. There-
fore, GIRK1 is thought to be able to act not only in cell
proliferation but also as an angiogenesis activator as well
as G-protein-coupled receptors. S-kinase-associated pro-
tein 2 (Skp2) plays a critical role in regulating cell cycle
progression and human factor-8-related antigen (F8RA) is
assessed to show angiogenesis by microvessel density. So
we determined whether or not expression of GIRK1
mRNA correlated with immunohistochemical assays of
Skp2 and F8RA. Patients with high expression of GIRK1
mRNA were tendency to show high MVD and positive
Skp2 expression without significance (data not shown).
GIRK1 could be a candidate for a pharmaceutical target,
depending upon further functional studies.
In this study, we used human pulmonary adenocarci-
noma cell line PC-14 as a positive control for GIRK1 gene
expression. The patients were classified into two groups
according to the cutoff point of mean ration of GIRK1/cell
line PC-14 expression in tumor specimens. The mean
number has been widely used as the cutoff point to divide
the patients into two groups [20,21]. GIRK1 was
expressed at higher levels in cancer tissue than in adjacent
normal lung tissue. It was shown that a high GIRK1 gene
expression was detected in 69% of the tumor samples in
our patient population with NSCLC. Furthermore, GIRK1
gene expression was also associated with nodal status, and
tumor stage. These results, in correlation with nodal sta-
tus, were similar to a previous report on breast carcinomas
[8]. We examined the relationships between GIRKI gene
expression and AMF-R gene expression, known as a
marker of lymph node metastasis and tumor progression
in NSCLC [12], and the results of GIRK1 gene expression
agreed significantly with AMF-R. Statistical associations
between GIRK1 expression and clinicopathological varia-
bles (age, T-factor, histology, and AMF-R) were examined
by regression analysis. This analysis also showed that
GIRK1 was correlated with AMF-R (data not shown). It
was observed that patients with high GIRK1 expression
NSCLC showed an unfavorable prognosis compared with
those whose tumors had low GIRK1 expression in overall.
Many patients in stage II/III disease had high GIRK1
expression than low GIRK1 expression. Therefore the
poorer survival in overall was possible to be due to stage.
So we compared patients in each stage, and we found a
positive correlation between GIRK1 expression and surgi-
cal outcome in stage I cancer but not a positive correlation
in stage II/III disease. Our results suggest that a high
GIRK1 gene expression was strongly associated with an
increased recurrence in stage I cancer and that patients
with high GIRK1 gene expression may be prone to metas-
tasis, or may already have occult micrometastasis to the
lymph node in stage I cancer. On the other hand, GIRK1
expression does not seem to be a prognostic predictor for
stage II/III disease individuals. GIRK1 gene expression
level may play one of a key role in the biology of lung can-
cer and define a more aggressive tumor phenotype. Fur-
ther studies are needed on GIRK1 to evaluate the
mechanism of GIRK1 and more studies with a larger
group of patients will be necessary to substantiate these
data. A real quantative PCR amplication is now the stand-
ard approach, and more sensitive and accurate than RT-
PCR. We would use the real-time quantative PCR ampli-
cation instead of RT-PCR in the next study for estimating
the gene expression.
In conclusion, the present study suggests GIRK1 may be
contribute to tumor progression and could be a useful
prognostic marker in patients with overall and stage I
NSCLC. Thus the current findings provide evidence to
support a potential utility of this gene in developing a
diagnostic test for NSCLC patients.
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